pcos treatment glp-1 Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? | Journal of Endocrinological Investigation Rising use of GLP-1 medications

That could shift

Rohm TV, Meier DT, Olefsky JM, Donath MY (2022) Inflammation in obesity, diabetes and related Disorders

Am J Alzheimers Dis Other Demen

Eular recommendations for the management of systemic lupus erythematosus: 2023 update

Society consensus statements and guidelines 2729 have subsequently integrated SGLT-2i and GLP-1RA under the umbrella term of glucose-lowering drugs with cardiovascular benefit and recommended their use in patients with T2D at high cardiovascular risk

This expansion comes after a 49% year-over-year increase in fiscal Q2 revenue ending December 31, 2024, in the U.S., largely driven by the systems success, and clinical data on that formula reinforcing its effectiveness in supporting GLP-1 production